Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2010-04-20 Interim / Quarterly Rep…
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed with the SEC by Novartis AG, reporting quarterly financial results for the first quarter of 2010. It includes detailed financial data such as net sales, operating income, net income, EPS, and free cash flow, along with management commentary on business performance, innovation, growth, and productivity initiatives. The presence of comprehensive financial figures and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document is not a brief announcement or a certification but a substantive financial report. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2010-04-20 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the acquisition of Oriel Therapeutics by Sandoz, a division of Novartis. It details the terms of the acquisition, strategic rationale, and background information about the companies involved. There are no financial statements, detailed financial analysis, or comprehensive management discussion typical of annual or interim reports. The document is an announcement of a corporate transaction and related strategic update rather than a full financial report or earnings release. It is not a certification or attestation document. Given the nature of the content and the form type (6-K), this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2010-04-20 English
F-3ASR
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment No. 1 to a Form F-3 Registration Statement filed with the SEC by Novartis AG and related entities. It includes exhibits, legal opinions, underwriting agreements, and signatures of officers and directors. The document is a regulatory filing related to securities registration under the Securities Act of 1933, specifically a post-effective amendment to a registration statement. It is not a financial report, earnings release, or management discussion. It is a formal SEC filing for securities registration and amendment, which fits the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed legal and procedural information rather than financial statements or report content. Therefore, the correct classification is Regulatory Filings (RNS).
2010-04-14 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release about clinical trial results and regulatory updates for a drug (Gilenia). It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is not an earnings release, call transcript, or management report. The document is a regulatory filing providing material information to investors but does not fit into more specific categories like capital updates, M&A, or governance. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not neatly fit into other categories. The document length (over 12,000 characters) and detailed content support this classification with high confidence.
2010-04-14 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release announcing the European Union approval of a vaccine product (Menveo). It is a regulatory announcement about a product approval and related clinical study data, not a financial report, earnings release, or management discussion. The document is lengthy (15,000 characters) and contains detailed information about the product and regulatory approval, but it is not a financial report or earnings announcement. It is a regulatory filing providing material information to investors and the SEC about a significant corporate event. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2010-03-19 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release about clinical trial results for a drug (aliskiren) and does not contain detailed financial statements or comprehensive financial analysis. The document is about a clinical trial outcome announcement rather than a financial report or earnings release. It is not an annual or interim report, nor is it a call transcript or management report. The document is a regulatory filing providing material information to investors but does not fit into more specific categories like earnings release or management reports. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (9327 characters) and content support this classification as it is a formal SEC filing but not a full financial report.
2010-03-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.